The recognition by Frost & Sullivan comes as we celebrate another milestone — helping patients get the medication they need more than 200 million times. As we surpass this milestone, we’ve got our eyes set on even bigger ways we can fulfill our mission as we expand our impact with solutions that support medication access and adherence throughout the patient journey.
With its focus on development, CoverMyMeds continues to solve some of the most common medication access challenges, including solutions beyond electronic prior authorization (ePA). The company expands its solutions with further innovations that bolster real-time prescription decision support, and cash discount programs show the cost of a medication without insurance. CoverMyMeds also provides an innovative, tech-driven approach to patient support services that streamlines patient access to specialty therapies and enables end-to-end visibility into the patient journey while accelerating time-to-therapy.Frost & Sullivan
Frost & Sullivan’s industry analyst team determines the award by benchmarking market participants and measuring their performance through independent, primary interviews and secondary industry research to evaluate and identify best practices.
CoverMyMeds leverages its innovative mindset and focuses on seamlessly connecting the healthcare network to improve medication access. With considerable experience in the field, the company commits to centering innovation on all stakeholders — ensuring its solutions provide high value to all.Frost & Sullivan
The recognition builds on our foundation of excellence and demonstrated success, as we were also honored by Frost & Sullivan in 2017 with a North American Visionary Innovation Leadership Award for prior authorization solutions.
To view the full Frost & Sullivan research report and methodology, click here.